AstraZeneca PLC (LSE:AZN) shares fell almost 7% in London trading after reports emerged that the pharmaceutical company has held discussions with Bristol-Myers Squibb Company (NYSE:BMY) regarding a potential merger. If completed, the transaction would create one of the world’s largest drugmakers, with a combined market value approaching $400 billion.
AstraZeneca’s shares declined 6.7% to 11,804 pence, while the FTSE 100 traded little changed. In the U.S., Bristol Myers Squibb rose 2.7% in pre-market trading after ending Friday’s session at $65.31, close to its highest level in the past 52 weeks.
Potential Deal Would Create a Global Pharmaceutical Leader
Based on current market valuations, a combined company would be worth nearly $400 billion. AstraZeneca has a market capitalisation of around $264 billion, while Bristol Myers Squibb is valued at approximately $133 billion.
According to a report by the Financial Times, citing people familiar with the matter, merger discussions have taken place over recent months. However, the report noted that negotiations remain preliminary and could ultimately be delayed or fail to result in an agreement. Neither company has publicly commented on the report, and no details regarding a possible transaction structure have been disclosed.
Investors Assess Strategic Implications
The reported discussions come at a time when both companies are pursuing ambitious growth strategies.
Under Chief Executive Pascal Soriot, AstraZeneca has transformed into one of the world’s largest pharmaceutical companies after rejecting Pfizer’s $118 billion takeover proposal in 2014. More recently, the company announced plans to invest $50 billion in U.S. manufacturing and research facilities while outlining its intention to pursue a direct U.S. stock market listing to broaden access to American investors.
For Bristol Myers Squibb, acquisitions have become an increasingly important part of its strategy as it seeks to strengthen its product pipeline ahead of upcoming patent expiries. The company has continued to expand its oncology and immunology portfolio through partnerships and business development initiatives, making a larger strategic combination a potential avenue for accelerating long-term growth.
Both Companies Recently Reported Strong Quarterly Results
The merger speculation follows solid quarterly earnings from both businesses.
AstraZeneca reported second-quarter earnings per share of $2.63, exceeding analyst expectations of $2.48, while revenue reached $15.38 billion, narrowly below the consensus forecast of $15.45 billion.
Bristol Myers Squibb also outperformed market expectations, delivering second-quarter earnings per share of $2.04 compared with forecasts of $1.61. Revenue totalled $12.97 billion, comfortably ahead of the $11.71 billion expected by analysts.
Over the past 12 months, Bristol Myers Squibb shares have gained nearly 48%, supported by improving earnings and renewed investor confidence.
Focus Turns to Upcoming Earnings
Investors are now looking ahead to the companies’ next quarterly updates for further insight into their strategic priorities.
Bristol Myers Squibb is scheduled to release third-quarter 2026 results on 29 October, with analysts forecasting earnings per share of $1.61 on revenue of approximately $12.04 billion. AstraZeneca is due to report one day later, with consensus estimates calling for earnings per share of $2.63 and revenue of around $16.06 billion.
Should either company announce a formal transaction before those reporting dates, it would likely reshape management commentary and future guidance, making the coming months a key period for investors monitoring developments.
Leave a Reply